Cart
sales@molnova.com
BZX1
CAS No. 371215-02-0
BZX1( —— )
Catalog No. M36277 CAS No. 371215-02-0
BZX1 is an O-Iinked N-acetylglucosaminyltransferase inhibitor, which can be used to study abnormal cell differentiation and cartilage degeneration.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBZX1
-
NoteResearch use only, not for human use.
-
Brief DescriptionBZX1 is an O-Iinked N-acetylglucosaminyltransferase inhibitor, which can be used to study abnormal cell differentiation and cartilage degeneration.
-
DescriptionBZX1 is an O-Iinked N-acetylglucosaminyltransferase inhibitor, which can be used to study abnormal cell differentiation and cartilage degeneration.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number371215-02-0
-
Formula Weight289.67
-
Molecular FormulaC14H8ClNO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(OC=1C=CC=CC1)N2C(=O)OC3=CC=C(Cl)C=C32
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Carpachromene
Carpachromene could be a potential anti-inflammatory agent, it blocks protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in LPS-stimulated macrophages.Carpachromene shows significant α-glucosidase inhibitory activity.
-
BAY 2416964
BAY 2416964 is a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1 (example 192, IC50: 341 nM). It has the potential for cancer treatment.BAY 2416964 induces AHR-regulated gene CYP1A1 expression in human monocytic U937 cells (IC50: 4.3 nM).
-
Vazegepant HCl
Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
